141 related articles for article (PubMed ID: 37515737)
1. Modeling population pharmacokinetics of morniflumate in healthy Korean men: extending pharmacometrics analysis to niflumic acid, its major active metabolite.
Jeong SH; Jang JH; Lee YB
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):843-856. PubMed ID: 37515737
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous determination of morniflumate and its major active metabolite, niflumic acid, in human plasma by high-performance liquid chromatography in stability and pharmacokinetic studies.
Cho HY; Park GK; Lee YB
Biomed Chromatogr; 2013 Nov; 27(11):1438-43. PubMed ID: 23722315
[TBL] [Abstract][Full Text] [Related]
3. Modulation of arachidonic acid metabolism by orally administered morniflumate in man.
Civelli M; Vigano T; Acerbi D; Caruso P; Giossi M; Bongrani S; Folco GC
Agents Actions; 1991 Jul; 33(3-4):233-9. PubMed ID: 1659152
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetic and bioequivalence evaluation of two formulations of morniflumate 350-mg tablets in healthy male subjects
.
Lee H; Yim SV; Kim BH; Lee S
Int J Clin Pharmacol Ther; 2017 Jan; 55(1):95-101. PubMed ID: 27841153
[TBL] [Abstract][Full Text] [Related]
5. A gastroprotective anti-inflammatory agent: the beta-morpholinoethyl ester of niflumic acid (morniflumate).
Schiantarelli P; Cadel S; Acerbi D
Agents Actions; 1984 Feb; 14(2):247-56. PubMed ID: 6608862
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of morniflumate for the treatment of symptoms associated with soft tissue inflammation.
Cremonesi G; Cavalieri L
J Int Med Res; 2015 Jun; 43(3):290-302. PubMed ID: 25921871
[TBL] [Abstract][Full Text] [Related]
7. Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic-Pharmacodynamic Modeling.
Jeong SH; Jang JH; Lee YB
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002021
[TBL] [Abstract][Full Text] [Related]
8. Short-term tolerability of morniflumate in patients with cutaneous hypersensitivity reactions to non-steroidal anti-inflammatory drugs.
Mero F; Nettis E; Aloia AM; Di Leo E; Ferrannini A; Vacca A
Int J Immunopathol Pharmacol; 2013; 26(1):247-50. PubMed ID: 23527729
[TBL] [Abstract][Full Text] [Related]
9. The solid state of anti-inflammatory morniflumate diniflumate: A cocrystalline salt.
Barrio M; Ceolin R; Robert B; Allouchi H; Teulon JM; Guéchot C; Tamarit JL; Rietveld IB
Int J Pharm; 2021 Dec; 610():121224. PubMed ID: 34710544
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of acute inflammatory pathology of the upper airway with morniflumate].
Marchioni CF; Livi E; Oliani C; Guerzoni P; Corona M
Riv Eur Sci Med Farmacol; 1990 Dec; 12(6):347-57. PubMed ID: 2132289
[TBL] [Abstract][Full Text] [Related]
11. [A new anti-inflammatory-analgesic-antipyretic, morniflumate, in the treatment of chronic recurring bronchitis].
Melica A; Donateo L; Gerardi R; Parenti M
Riv Eur Sci Med Farmacol; 1991; 13(1-2):51-60. PubMed ID: 1796197
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled multicentre trial of the efficacy and tolerance of morniflumate suppositories in the treatment of tonsillitis in children.
Manach Y; Ditisheim A
J Int Med Res; 1990; 18(1):30-6. PubMed ID: 2110537
[TBL] [Abstract][Full Text] [Related]
13. Detection of the non-steroidal anti-inflammatory drug niflumic acid in humans: a combined 19F-MRS in vivo and in vitro study.
Bilecen D; Schulte AC; Kaspar A; Küstermann E; Seelig J; Elverfeldt D; Scheffler K
NMR Biomed; 2003 May; 16(3):144-51. PubMed ID: 12884358
[TBL] [Abstract][Full Text] [Related]
14. Nose Temperature and Anticorrelation between Recrystallization Kinetics and Molecular Relaxation Dynamics in Amorphous Morniflumate at High Pressure.
Romanini M; Rodriguez S; Valenti S; Barrio M; Tamarit JL; Macovez R
Mol Pharm; 2019 Aug; 16(8):3514-3523. PubMed ID: 31274326
[TBL] [Abstract][Full Text] [Related]
15. Effect of food on systemic exposure to niflumic acid following postprandial administration of talniflumate.
Kang W; Kim K; Kim EY; Kwon KI; Bang JS; Yoon YR
Eur J Clin Pharmacol; 2008 Oct; 64(10):1027-30. PubMed ID: 18607579
[TBL] [Abstract][Full Text] [Related]
16. Gastroprotective effects of morniflumate, an esterified anti-inflammatory drug.
Schiantarelli P; Cadel S; Folco GC
Arzneimittelforschung; 1984; 34(8):885-90. PubMed ID: 6333880
[TBL] [Abstract][Full Text] [Related]
17. Morniflumate-induced urticaria-angioedema.
Matheu V; Sierra Z; Gracia MT; Caloto M; Alcazar MM; Martinez MI; Zapatero L
Allergy; 1998 Aug; 53(8):812-3. PubMed ID: 9722233
[No Abstract] [Full Text] [Related]
18. [Lyell syndrome following administration of erythromycin-sulfafurazole and morniflumate].
Raymond F; Paillat A; Gambert C; Garnier P
Arch Pediatr; 1995 May; 2(5):494-5. PubMed ID: 7640747
[No Abstract] [Full Text] [Related]
19. [Controlled clinical study on the use of morniflumate in the treatment of inflammatory-degenerative diseases of the locomotor system].
Raffaetà G; Saponati G; Terzuoli A
G Clin Med; 1987 Oct; 68(10):507-13. PubMed ID: 3428515
[No Abstract] [Full Text] [Related]
20. [Efficacy and tolerability of morniflumate in acute otitis in infants: results of a randomized study versus placebos].
Portmann M; Portmann D; Rohou S; Pollet M; Colson J; Cuvelier A; Fournier JL; Jeannerot F; Marx J; Menet V
Rev Laryngol Otol Rhinol (Bord); 1990; 111(5):507-10. PubMed ID: 2087618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
